Forecast
Period
|
2026-2030
|
Market
Size (2024)
|
USD
660.52 Million
|
Market
Size (2030)
|
USD
1004.73 Million
|
CAGR
(2025-2030)
|
7.20%
|
Fastest
Growing Segment
|
Antidepressants
|
Largest
Market
|
North
America
|
Market Overview
Global Binge-eating Disorder
Treatment Market was valued at USD 660.52 Million in 2024 and is anticipated to project impressive
growth in the forecast period with a CAGR of 7.20% through 2030. Binge-eating
disorder (BED) is a prevalent and severe eating disorder characterized by
recurring episodes of consuming large quantities of food, often accompanied by
a lack of control. This mental health condition affects millions of individuals
worldwide, making it a significant concern for both public health and
healthcare providers. As awareness of BED increases and its diagnosis becomes
more precise, the global market for BED treatment has witnessed substantial
growth. Binge-eating disorder is not just about overeating; it's a complex
mental health condition with numerous psychological, social, and physical
consequences. Those suffering from BED often feel intense guilt, shame, and
distress, which can exacerbate the disorder and affect their overall quality of
life. As the world becomes more conscious of mental health issues, there's a
growing need for effective BED treatments.
Increased awareness about BED and its effects has
led to more individuals seeking diagnosis and treatment. This has driven the
demand for BED therapies and interventions. The ongoing advocacy for mental
health awareness and the reduction of stigmas surrounding eating disorders have
played a crucial role in driving the BED treatment market. The development of
medications specifically designed for BED treatment has been a significant
contributor to market growth. Some of these medications have shown promise in
reducing binge-eating episodes. Various therapeutic approaches, including
cognitive-behavioral therapy and dialectical behavior therapy, have proven
effective in treating BED. The demand for therapy services has consequently
risen.
Key Market Drivers
Rising Prevalence of Eating Disorders
The rising prevalence of eating disorders, particularly
binge-eating disorder (BED), is a critical driver of growth in the global BED
treatment market. Binge-eating disorder is one of the most common eating
disorders worldwide, affecting millions of individuals across various
demographic groups. An estimated 9% of the U.S. population, equivalent to 28.8 million individuals, are expected to experience an eating disorder at some point in their lifetime. Among women, approximately 15% will face an eating disorder during their 40s or 50s. However, only 27% of those affected receive any form of treatment, highlighting a significant gap in the accessibility and utilization of eating disorder care services. With a growing number of reported cases due to lifestyle
changes, urbanization, and the impact of stress on mental health, the market
for BED treatments is expanding to meet the needs of this growing patient
population. The condition is now more widely recognized, and diagnostic
criteria are better defined, which has led to higher identification rates and,
consequently, a surge in demand for treatment options. Approximately 25% of individuals diagnosed with eating disorders are male, underscoring a notable presence of the condition among this demographic. Additionally, 33% of males report engaging in unhealthy behaviors as part of efforts to modify their weight. Over the course of their lifetimes, eating disorders are projected to affect 10 million males, emphasizing a critical need for targeted treatment and intervention strategies within this underserved group. Modern lifestyles,
characterized by irregular eating habits, emotional eating, and increased
exposure to stressors, have contributed to a surge in BED cases. Furthermore,
BED is often associated with obesity, diabetes, and cardiovascular issues,
making it a public health priority. These comorbidities drive demand for
integrated treatment solutions, including pharmacological and
non-pharmacological approaches.
The stigma
surrounding mental health issues, including eating disorders, is gradually
diminishing due to awareness campaigns by healthcare organizations,
governments, and advocacy groups. As more individuals come forward to seek
help, the demand for accessible and effective BED treatments increases. This
shift has encouraged healthcare providers and pharmaceutical companies to
develop innovative solutions tailored to this growing patient base. In emerging
economies, where BED has traditionally been underdiagnosed or overlooked,
rising awareness and improved access to healthcare are uncovering significant
unmet needs. As a result, pharmaceutical companies, mental health clinics, and
therapy providers are focusing on these regions to capitalize on the growing
patient pool. BED, if left untreated, imposes a substantial economic burden on
individuals, healthcare systems, and society at large. This has prompted
increased investment in early diagnosis and treatment programs, further
bolstering the market for BED-specific therapies. The influence of social media
and modern communication channels has heightened awareness about eating
disorders, particularly among younger generations. Conversations around mental
health and body positivity have led to increased recognition of BED symptoms,
driving individuals to seek professional help and fueling market growth. The rising
prevalence of binge-eating disorder represents a significant opportunity for
stakeholders in the global treatment market. By addressing the growing demand
through innovative therapies, accessible mental health services, and targeted
awareness initiatives, the industry is positioned to experience sustained
growth in the coming years.
Growing Awareness About Mental Health
Growing awareness about mental health plays a pivotal role in driving the expansion of the global Binge-eating disorder (BED) treatment market. Mental disorders globally contribute to 1 in 6 years lived with disability, reflecting their significant impact on overall health. Individuals with severe mental health conditions face a reduced life expectancy of 10 to 20 years compared to the general population. Moreover, mental health conditions are closely linked to a heightened risk of suicide and human rights violations, underscoring the urgent need for comprehensive intervention and protection strategies. This increased awareness is transforming societal attitudes, healthcare priorities, and consumer behavior, creating a strong demand for innovative and effective BED treatment solutions. In recent years, there has been a notable reduction in the stigma surrounding mental health disorders, including eating disorders like BED. This shift is a result of global advocacy campaigns, media representation, and open discussions led by governments, non-profits, and influencers. As individuals feel more comfortable acknowledging and addressing mental health issues, the demand for treatment services and solutions for BED has grown significantly. Awareness campaigns have led to better recognition of BED symptoms among patients, families, and healthcare providers. Improved understanding of the disorder—characterized by recurrent episodes of consuming large amounts of food, often accompanied by guilt or distress—has encouraged more individuals to seek early diagnosis and intervention. This has expanded the pool of patients seeking treatment, driving growth in the market for BED therapies.
Governments and international organizations have begun prioritizing mental health as an integral component of public health strategies. Initiatives like subsidized mental health programs, inclusion of eating disorders in healthcare policies, and insurance coverage for BED treatments have made professional care more accessible and affordable. A study by the National Institute of Mental Health and Neurosciences (NIMHANS) in India identified a 2.4% prevalence of eating disorders within the general population. Meanwhile, a survey by the Indian Psychiatric Society revealed that 7.8% of adolescent girls in India are affected by eating disorders. In comparison, among adolescent girls in the United States, an estimated 14% exhibit symptoms of eating disorders, highlighting significant regional variations and a growing need for targeted interventions in both countries. This institutional support significantly enhances the reach and adoption of BED treatments. Mental health education in schools, workplaces, and community programs is fostering greater awareness about eating disorders. These efforts not only help individuals identify BED symptoms in themselves and others but also encourage a proactive approach to seeking help. This societal shift creates a growing consumer base for pharmaceuticals, therapy providers, and digital health platforms offering BED treatment. As awareness increases, more patients and providers recognize the need for comprehensive treatment approaches that combine psychological counseling, behavioral therapies (e.g., CBT), and pharmacological solutions. The demand for such holistic care models drives innovation and investment in the BED treatment market. Media campaigns, documentaries, and digital platforms have been instrumental in highlighting the impacts of binge-eating disorder and promoting recovery stories. Simultaneously, the rise of telehealth services and mobile applications has made mental health resources more accessible, further boosting treatment adoption rates.
Increasingly, corporations are implementing mental health initiatives to support employee well-being. Workplace wellness programs often include resources for addressing eating disorders, indirectly driving the demand for BED treatment solutions in the form of therapy, online platforms, or partner healthcare providers. As consumers become more informed, there is a growing expectation for high-quality, effective, and convenient mental health solutions. This demand has spurred pharmaceutical companies, digital health platforms, and therapy providers to invest in research and development of innovative BED treatments. Cross-border collaboration among healthcare providers, researchers, and policymakers is fostering the development of best practices for BED treatment. This international exchange of knowledge and resources is enhancing the quality and accessibility of care, particularly in underserved regions. The growing awareness about mental health is a transformative force driving the global BED treatment market. By reducing stigma, improving access to care, and encouraging early diagnosis, this trend creates opportunities for healthcare providers, pharmaceutical companies, and digital platforms to expand their reach. As mental health continues to gain prominence in public discourse and policy, the BED treatment market is poised for sustained growth. Businesses that leverage this trend by offering innovative, patient-centered solutions will be well-positioned to thrive in this evolving landscape.
Increased Healthcare Expenditure
Increased healthcare expenditure is a critical factor driving the growth of the global Binge-Eating Disorder (BED) treatment market. The report highlights that global health spending reached $9.8 trillion in 2021, accounting for 10.3% of global GDP, driven by increased government expenditure and out-of-pocket costs during the second year of the pandemic. In low-income countries, external health aid played a crucial role in supplementing government budgets. However, maintaining 2021 levels of government spending and external aid poses significant challenges amid worsening global economic conditions, rising inflation, and growing debt servicing obligations, raising concerns about the sustainability of health financing in vulnerable economies. The rise in public and private spending on healthcare across the globe has created an environment where better diagnostic tools, therapeutic solutions, and overall access to treatment for mental health disorders, including BED, are being prioritized. Higher healthcare budgets enable governments and private healthcare institutions to expand mental health services, including diagnostic tools and treatment options for BED. Increased spending facilitates the establishment of specialized centers, clinics, and programs that cater to eating disorders, thereby broadening the market for BED-related treatments. A surge in healthcare expenditure supports innovation in pharmaceutical research and therapeutic techniques. Companies are investing more in the development of cutting-edge solutions, such as FDA-approved medications like lisdexamfetamine (Vyvanse), and advancements in psychotherapy approaches like Cognitive Behavioral Therapy (CBT). This innovation pipeline accelerates the availability of effective treatments, directly fueling market growth. Mental health disorders, including BED, have historically been underfunded. However, with growing recognition of their societal and economic impact, a greater proportion of healthcare budgets is now being allocated to mental health infrastructure. This includes training healthcare professionals, increasing the number of treatment facilities, and integrating mental health services into primary care systems, ensuring BED treatment reaches a wider audience.
Rising healthcare spending often correlates with broader insurance coverage for mental health services. In many countries, governments and private insurers are expanding their policies to cover eating disorder treatments, including psychotherapy, medications, and counseling services. This reduces the financial burden on patients and encourages more individuals to seek professional help, driving market demand. Rapid economic development in emerging markets such as India, China, and Brazil has led to increased healthcare expenditure in these regions. As governments and private sectors in these countries invest in improving their healthcare systems, there is a growing emphasis on addressing mental health issues, including BED. This unlocks new growth opportunities for BED treatment providers in previously underserved markets. Binge-eating disorder is often associated with comorbidities such as obesity, diabetes, depression, and anxiety, which also receive significant attention in healthcare budgets. Higher spending on managing these conditions includes investment in therapies that address the root causes, such as BED, further driving demand for its treatment. Increased healthcare budgets enable investments in telehealth platforms, mobile health apps, and online therapy solutions. These technologies improve access to BED treatment, particularly in remote or underserved areas. This trend not only broadens the reach of existing treatments but also attracts a tech-savvy population to seek care, boosting market growth.
Higher healthcare spending fosters collaboration between public institutions and private companies to address eating disorders like BED. For instance, governments may partner with pharmaceutical firms or mental health organizations to subsidize treatment costs or support large-scale awareness campaigns, creating a positive feedback loop for market growth. Increased expenditure fuels investment in research and development (R&D) for novel BED treatments. Pharmaceutical companies and research institutions are better equipped to explore new therapeutic pathways, develop personalized medicine approaches, and conduct clinical trials. This accelerates the introduction of new, more effective treatments into the market. BED poses a significant economic burden on individuals and healthcare systems due to its association with reduced productivity, absenteeism, and long-term health complications. Governments and organizations are increasingly allocating resources to address these costs by prioritizing effective treatment options, further driving market growth. Increased healthcare expenditure creates a fertile environment for the growth of the global BED treatment market by improving access, fostering innovation, and expanding the reach of mental health services. As governments and private stakeholders continue to invest in healthcare infrastructure and mental health solutions, businesses in the BED treatment space are presented with significant opportunities to grow and innovate. Organizations that align their strategies with these spending trends—focusing on accessibility, affordability, and innovation—stand to benefit greatly in this expanding market.

Download Free Sample Report
Key Market Challenges
Stigma and Awareness
One of the primary challenges in the BED treatment
market is the persistence of stigma surrounding eating disorders, including
BED. Many individuals suffering from BED do not seek help due to fear of
judgment or misunderstanding of their condition. This lack of awareness not
only delays diagnosis and treatment but also limits the market's potential for
growth. Efforts to educate the public and healthcare professionals about BED
are essential. This includes challenging the misconception that BED is simply a
lack of self-control rather than a complex mental health issue. Overcoming
stigma remains a significant obstacle in increasing patient engagement in
treatment and driving market expansion.
Diagnosis and Screening
BED often goes undiagnosed or misdiagnosed as other
eating disorders or mental health conditions, such as bulimia or depression. To
effectively treat BED, early and accurate diagnosis is crucial. However,
healthcare providers face challenges in implementing standardized screening and
diagnostic protocols. Improving the accuracy of diagnosis through screening
tools and training for healthcare professionals is a pressing issue. The
development of effective diagnostic tools can enhance the treatment market by ensuring
that individuals receive appropriate care.
Treatment Options
The variety of treatment options for BED remains
somewhat limited compared to other eating disorders. While cognitive-behavioral
therapy (CBT) has shown effectiveness in treating BED, not all patients respond
well to this approach. Pharmaceutical treatments are also being explored, but
the approval and market adoption of such drugs face regulatory hurdles and
challenges related to safety and efficacy. Research into alternative treatment
modalities, personalized therapy plans, and innovative medications is crucial
to provide tailored approaches to individuals with BED. Expanding the range of
available treatments is a key factor in addressing the challenges faced by the
BED treatment market.
Access to Care
Access to appropriate care for BED remains a
significant challenge in many regions. Financial barriers, lack of specialized
treatment centers, and inadequate insurance coverage often prevent individuals
from seeking the help they need. This results in underutilization of existing
treatment options and hampers market growth. Addressing these challenges
involves expanding access to affordable and evidence-based treatment options,
increasing mental health parity in insurance policies, and developing a network
of healthcare providers trained in BED treatment.
Research and Data Gaps
There is still much to learn about BED, its causes,
and the most effective treatment approaches. The BED treatment market requires
a robust foundation of research and data to guide advancements. Gaps in our
understanding of the condition, including its genetic, neurobiological, and
psychosocial underpinnings, hinder the development of targeted therapies. Investment
in research and data collection is critical for overcoming these challenges.
Collaboration between researchers, healthcare professionals, and pharmaceutical
companies is needed to advance our knowledge of BED and develop more effective
treatments.
Key Market Trends
Technological Advancements
Technological advancements have greatly improved
the ability to diagnose binge-eating disorders. Machine learning algorithms and
artificial intelligence (AI) tools can analyze patient data, such as medical
history, food diaries, and even voice and text analysis, to detect patterns
indicative of BED. These tools can assist healthcare professionals in making
earlier and more accurate diagnoses, which is crucial for effective
intervention. Telemedicine has become a
crucial component of healthcare, especially in the context of mental health
conditions like BED. Patients can now connect with therapists and healthcare
providers remotely, ensuring regular check-ins and consistent support.
Telemedicine apps and platforms also enable the monitoring of food intake,
emotions, and progress over time. This has been a game-changer, as it allows
patients to receive help from the comfort of their own homes, reducing the
barriers to seeking treatment. Digital therapeutics, often
in the form of smartphone apps, are revolutionizing the treatment of
binge-eating disorder. These applications provide patients with tools for
tracking their eating habits, setting goals, and practicing mindfulness. They
often employ cognitive-behavioural therapy (CBT) techniques, which are highly
effective in treating BED. Digital therapeutics not only enhance the efficacy
of treatment but also improve patient engagement and adherence to therapy.
Wearable devices, such as
smartwatches and fitness trackers, have integrated features that enable
individuals to monitor their physical activity, heart rate, and sleep patterns.
These devices can be instrumental in helping individuals with binge-eating disorder
by fostering healthier lifestyles. By promoting regular exercise and improved
sleep quality, they contribute to better overall well-being and can indirectly
aid in the treatment process. The collection and analysis
of big data have opened up new possibilities for understanding and treating
BED. By analysing large datasets, researchers and healthcare providers can
identify trends, risk factors, and potential treatment responses. This enables
more personalized treatment plans tailored to each patient's unique needs,
increasing the chances of success.
Segmental Insights
Type Insights
Based on the category of Type, Antidepressants emerged
as the dominant in the global market for Binge-eating Disorder Treatment
in 2024. Antidepressants are a class of medications that have been found to be
effective in treating binge-eating disorder. These drugs were initially
developed to alleviate symptoms of depression, but their impact on BED is now
widely recognized. Specifically, selective serotonin reuptake inhibitors
(SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have shown
promise in reducing the frequency and severity of binge-eating episodes. Antidepressants
target the brain's neurotransmitters, such as serotonin and norepinephrine,
which are associated with mood regulation. By improving mood and reducing
symptoms of depression and anxiety, these medications can reduce the emotional
triggers that lead to binge-eating. Some antidepressants, like bupropion, can
reduce appetite, making it easier for patients to control their food intake and
resist the urge to binge. Antidepressants can enhance a patient's ability to
resist impulsive behavior, which is often a significant factor in binge-eating
episodes.

Download Free Sample Report
Regional Insights
North America emerged as the dominant in the
global Binge-eating Disorder Treatment market in 2024, holding the largest
market share in terms of value. North America, particularly the United States
and Canada, has some of the highest prevalence rates of binge-eating disorder
in the world. This has led to a greater demand for effective treatments and a
more extensive market for pharmaceutical companies and treatment providers. In the United States, the lifetime prevalence of eating disorders is approximately 0.80% for anorexia nervosa, 0.28% for bulimia nervosa, and 0.85% for binge eating disorder. Alarming statistics highlight the severe consequences of this issue, with one person dying from an eating disorder every 52 minutes, as reported by the Academy for Eating Disorders. The pressure to conform to unrealistic body ideals, often amplified by social media, is contributing to this growing crisis, emphasizing the urgent need for effective treatment solutions and broader public awareness.
Recent Developments
- In June 2024, Researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London have developed a new home-administered treatment for binge eating disorder that demonstrates promising outcomes. This innovative approach integrates transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique, with a structured training program designed to address maladaptive patterns of attention related to food.
- In May 2024, A recent study published in JAMA Network Open evaluated the effectiveness of web-based self-help interventions in treating binge eating disorder (BED). The findings demonstrate that these online programs offer a viable and effective solution for alleviating BED symptoms, highlighting the potential for scalable, accessible treatment options in managing the disorder. This research positions digital health solutions as a promising avenue for expanding access to care and improving patient outcomes.
- In September 2023, Advisers not affiliated with the
US Food and Drug Administration convene to deliberate on matters pertaining to
the rules, ethical considerations, and the potential of developing an
artificial womb with the aim of improving the survival prospects of extremely
premature infants, while minimizing any enduring health issues. The region
boasts an advanced healthcare infrastructure with well-established mental
health facilities and medical centers. These resources facilitate early
diagnosis, intervention, and effective treatment for individuals suffering from
BED. North America leads in research and development, with a significant focus
on mental health and eating disorders. This has led to the development of
cutting-edge treatment options, including therapy, medication, and innovative
interventions.
- In April 2023, New research led by the Perelman School of Medicine at the University of Pennsylvania has uncovered significant changes in the neural circuits responsible for habit formation in individuals with binge eating disorder (BED). The study, published in Science Translational Medicine, reveals that these habit circuits in the brain are altered in BED patients compared to those without the disorder. This breakthrough provides valuable insights into the neurological underpinnings of BED, potentially paving the way for more targeted and effective treatments that address the root causes of habitual eating behaviors.
Key Market Players
- Viatris Inc.
- Johnson & Johnson Services, Inc.
- Lupin Ltd.
- Omeros Corp.
- Pyramid Healthcare Inc.
- Sumitomo Pharma Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Eli Lilly and Co
- Tonix Pharmaceuticals Holding Corp.
- Tryp Therapeutics Inc.
By Type
|
By Distribution Channel
|
By Region
|
- Antidepressants
- Anticonvulsants
- Stimulants
- Others
|
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Binge-eating Disorder
Treatment Market has been segmented into the following categories, in addition
to the industry trends which have also been detailed below:
- Binge-eating Disorder Treatment Market, By Type:
o Antidepressants
o Anticonvulsants
o Stimulants
o Others
- Binge-eating Disorder Treatment Market, By Distribution Channel:
o Offline
o Online
- Binge-eating Disorder Treatment Market, By
Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Binge-eating
Disorder Treatment Market.
Available Customizations:
Global Binge-eating Disorder Treatment market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Binge-eating
Disorder Treatment Market is an upcoming report to be released soon. If you
wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]